S

Cassava Sciences, Inc.

SAVA US

Cassava Sciences, Inc.United States Composite

18.81

USD
-0.32
(-1.67%)
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Remi Barbier
Full Time Employees
26
Sector
Healthcare
Industry
Biotechnology
Address
6801 N. Capital of Texas Hwy, Bldg 1 Austin TX United States 78731
IPO Date
Jul 14, 2000
Business
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.